Renalytix (LSE:RENX) Debt-to-Equity : 3.18 (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Renalytix Debt-to-Equity?

Renalytix's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was £2.51 Mil. Renalytix's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was £4.20 Mil. Renalytix's Total Stockholders Equity for the quarter that ended in Dec. 2023 was £2.11 Mil. Renalytix's debt to equity for the quarter that ended in Dec. 2023 was 3.18.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Renalytix's Debt-to-Equity or its related term are showing as below:

LSE:RENX' s Debt-to-Equity Range Over the Past 10 Years
Min: -7.08 Med: 0.02 Max: 3.18
Current: 3.18

During the past 6 years, the highest Debt-to-Equity Ratio of Renalytix was 3.18. The lowest was -7.08. And the median was 0.02.

LSE:RENX's Debt-to-Equity is ranked worse than
93.12% of 552 companies
in the Healthcare Providers & Services industry
Industry Median: 0.49 vs LSE:RENX: 3.18

Renalytix Debt-to-Equity Historical Data

The historical data trend for Renalytix's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Renalytix Debt-to-Equity Chart

Renalytix Annual Data

Trend

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Debt-to-Equity

Get a 7-Day Free Trial

0.02

0.40

1.74

Renalytix Quarterly Data
	Dec18	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															1.37	0.64	1.74	-7.08	3.18

Competitive Comparison of Renalytix's Debt-to-Equity

For the Health Information Services subindustry, Renalytix's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Renalytix's Debt-to-Equity Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Renalytix's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Renalytix's Debt-to-Equity falls into.

Renalytix Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Renalytix's Debt to Equity Ratio for the fiscal year that ended in Jun. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(3.638	+	5.961)	/	5.518
	=	1.74

Renalytix's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(2.513	+	4.195)	/	2.107
	=	3.18

Renalytix (LSE:RENX) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Renalytix Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Renalytix's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Renalytix (LSE:RENX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Renalytix PLC (LSE:RENX) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

RNLX:USA RTNXF:USA 2O9:Germany

Address

5-7 Cranwood Street, Finsgate, London, GBR, EC1V 9EE

Website

https://www.renalytix.com

Renalytix PLC is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the common and costly chronic medical conditions globally. The company's product is KidneyIntelX which is being designed to make improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery.

Renalytix (LSE:RENX) Headlines

From GuruFocus

Causeway International's Top Five Holdings

By Monica Wolfe Monica Wolfe • 08-29-2013

Paul Singer Buys Reed Elesvier

By matsandalex matsandalex • 12-14-2012

Investing in Information

By Vanina Egea Vanina Egea • 03-06-2014

Omnicom Health Group acquires Elsevier's Pharma Communications business in Japan, rebrands as EMC K.K.

By PRNewswire PRNewswire • 03-27-2018